QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=2363F101D2D447D4CBD714B7E64360A2;jsessionid=03112DD9042173300A1C516437A6826B;jsessionid=74FB2F60B6BB69F12CD0D3223D789086;jsessionid=CE75A03774E3B8D9F88BDC161431EACF;jsessionid=7590C11F35E31F30FDD28D77B8CAB368 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=2363F101D2D447D4CBD714B7E64360A2;jsessionid=03112DD9042173300A1C516437A6826B;jsessionid=74FB2F60B6BB69F12CD0D3223D789086;jsessionid=CE75A03774E3B8D9F88BDC161431EACF;jsessionid=7590C11F35E31F30FDD28D77B8CAB368